These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 22978629)

  • 1. Estimating the lifetime economic burden of Parkinson's disease in Singapore.
    Zhao YJ; Tan LC; Au WL; Heng DM; Soh IA; Li SC; Luo N; Wee HL
    Eur J Neurol; 2013 Feb; 20(2):368-74. PubMed ID: 22978629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic burden of Parkinson's disease in Singapore.
    Zhao YJ; Tan LC; Li SC; Au WL; Seah SH; Lau PN; Luo N; Wee HL
    Eur J Neurol; 2011 Mar; 18(3):519-26. PubMed ID: 20840378
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The economic cost of myopia in adults aged over 40 years in Singapore.
    Zheng YF; Pan CW; Chay J; Wong TY; Finkelstein E; Saw SM
    Invest Ophthalmol Vis Sci; 2013 Nov; 54(12):7532-7. PubMed ID: 24159089
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Costs of Parkinson's disease in eastern Europe: a Czech cohort study.
    Winter Y; von Campenhausen S; Brozova H; Skoupa J; Reese JP; Bötzel K; Eggert K; Oertel WH; Dodel R; Ruzicka E
    Parkinsonism Relat Disord; 2010 Jan; 16(1):51-6. PubMed ID: 19665915
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic burden of Parkinson's disease in a developing country: a retrospective cost analysis in Shanghai, China.
    Wang G; Cheng Q; Zheng R; Tan YY; Sun XK; Zhou HY; Ye XL; Wang Y; Wang Z; Sun BM; Chen SD
    Mov Disord; 2006 Sep; 21(9):1439-43. PubMed ID: 16773620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic burden of schizophrenia: empirical analyses from a survey in Thailand.
    Phanthunane P; Whiteford H; Vos T; Bertram M
    J Ment Health Policy Econ; 2012 Mar; 15(1):25-32. PubMed ID: 22611090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resource use and costs in a Swedish cohort of patients with Parkinson's disease.
    Hagell P; Nordling S; Reimer J; Grabowski M; Persson U
    Mov Disord; 2002 Nov; 17(6):1213-20. PubMed ID: 12465059
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of conjugate pneumococcal vaccination in Singapore: comparing estimates for 7-valent, 10-valent, and 13-valent vaccines.
    Tyo KR; Rosen MM; Zeng W; Yap M; Pwee KH; Ang LW; Shepard DS
    Vaccine; 2011 Sep; 29(38):6686-94. PubMed ID: 21745516
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Burden of illness in Parkinson's disease.
    Huse DM; Schulman K; Orsini L; Castelli-Haley J; Kennedy S; Lenhart G
    Mov Disord; 2005 Nov; 20(11):1449-54. PubMed ID: 16007641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Impact of motor and non-motor symptoms on the direct costs of Parkinson's disease].
    Cubo E; Martínez Martin P; González M; Frades B;
    Neurologia; 2009; 24(1):15-23. PubMed ID: 19003550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An economic model of Parkinson's disease: implications for slowing progression in the United States.
    Johnson SJ; Diener MD; Kaltenboeck A; Birnbaum HG; Siderowf AD
    Mov Disord; 2013 Mar; 28(3):319-26. PubMed ID: 23404374
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Costs of illness in a Russian cohort of patients with Parkinson's disease.
    Winter Y; von Campenhausen S; Popov G; Reese JP; Klotsche J; Bötzel K; Gusev E; Oertel WH; Dodel R; Guekht A
    Pharmacoeconomics; 2009; 27(7):571-84. PubMed ID: 19663528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The current and projected economic burden of Parkinson's disease in the United States.
    Kowal SL; Dall TM; Chakrabarti R; Storm MV; Jain A
    Mov Disord; 2013 Mar; 28(3):311-8. PubMed ID: 23436720
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of pergolide compared to bromocriptine in the treatment of Parkinson's disease: a decision-analytic model.
    Davey P; Rajan N; Lees M; Aristides M
    Value Health; 2001; 4(4):308-15. PubMed ID: 11705298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug and treatment costs in Parkinson's disease patients in Sweden.
    Lökk J; Borg S; Svensson J; Persson U; Ljunggren G
    Acta Neurol Scand; 2012 Feb; 125(2):142-7. PubMed ID: 21470194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost of Parkinson's disease among Filipino patients seen at a public tertiary hospital in Metro Manila.
    Prado M; Jamora RD
    J Clin Neurosci; 2020 Apr; 74():41-46. PubMed ID: 31983646
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of health-care costs involved in treating people with and without Parkinson's disease in Southern Sydney, New South Wales, Australia.
    Cordato DJ; Schwartz R; Abbott E; Saunders R; Morfis L
    J Clin Neurosci; 2006 Jul; 13(6):655-8. PubMed ID: 16797991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of deep brain stimulation in patients with Parkinson's disease.
    Dams J; Siebert U; Bornschein B; Volkmann J; Deuschl G; Oertel WH; Dodel R; Reese JP
    Mov Disord; 2013 Jun; 28(6):763-71. PubMed ID: 23576266
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early retirement and income loss in patients with early and advanced Parkinson's disease.
    Johnson S; Davis M; Kaltenboeck A; Birnbaum H; Grubb E; Tarrants M; Siderowf A
    Appl Health Econ Health Policy; 2011 Nov; 9(6):367-76. PubMed ID: 21919541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What are the issues facing Parkinson's disease patients at ten years of disease and beyond? Data from the NPF-QII study.
    Hassan A; Wu SS; Schmidt P; Malaty IA; Dai YF; Miyasaki JM; Okun MS
    Parkinsonism Relat Disord; 2012 Dec; 18 Suppl 3():S10-4. PubMed ID: 22776044
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.